Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency 10.06.2022 / 07:00 The issuer is solely responsible for the content of this announcement. PRESS ...

PARAMUS, N.J., Jan. 7, 2026 /PRNewswire/ -- Octapharma USA, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new 2-gram presentation of Fibryga ®, Fibrinogen (Human ...

What Is Fesilty, and Why Does It Matter? Fesilty (fibrinogen, human-chmt) is a newly approved treatment for sudden bleeding episodes in both children and adults with a rare condition called congenital ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for ...

DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today ...

Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate 14.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS ...

In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard ...

PARAMUS, N.J, Aug. 1, 2024 /PRNewswire/ -- Octapharma USA, Inc. has announced the expanded approval of fibryga ®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for fibrinogen replacement ...

The human fibrinogen concentrate market is on a steady growth propelled by several pivotal factors. There is rise in global incidence of bleeding disorders necessitating the utilization of human ...

The MarketWatch News Department was not involved in the creation of this content. PARAMUS, N.J., Jan. 7, 2026 /PRNewswire/ -- Octapharma USA, Inc. today announced that the U.S. Food and Drug ...